Return to Statistics Toolbox

Pathway mapping for Study ST003657

(Analysis All analyses used)
Select one or more experimental factors for Groups 1 and 2. The members of each group should be DIFFERENT.
Group1Experimental factorGroup2
Sample source:U251 | Condition:anti-GLS1 siRNA | Method of exposure:Transfection (3)
Sample source:U251 | Condition:Control | Method of exposure:Direct exposure (5)
Sample source:U251 | Condition:Control | Method of exposure:Transfection (3)
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3 (4)
Sample source:U251 | Condition:Control | Method of exposure:Transwell b.End3 + iNHA (5)
Sample source:U251 | Condition:Lipofectamine | Method of exposure:Transfection (3)
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure (5)
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 (5)
Sample source:U251 | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA (5)
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Direct exposure (5)
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 (5)
Sample source:U251 | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA (5)
Sample source:U-87MG | Condition:anti-GLS1 siRNA | Method of exposure:Transfection (3)
Sample source:U-87MG | Condition:Control | Method of exposure:Direct exposure (5)
Sample source:U-87MG | Condition:Control | Method of exposure:Transfection (3)
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3 (4)
Sample source:U-87MG | Condition:Control | Method of exposure:Transwell b.End3 + iNHA (6)
Sample source:U-87MG | Condition:Lipofectamine | Method of exposure:Transfection (3)
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Direct exposure (5)
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 (5)
Sample source:U-87MG | Condition:PUREG4-LA12-anti-GLS1 siRNA | Method of exposure:Transwell b.End3 + iNHA (6)
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Direct exposure (5)
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 (5)
Sample source:U-87MG | Condition:PUREG4-LA12 | Method of exposure:Transwell b.End3 + iNHA (6)
Limit by pathway class:
Analysis:Combine data for all analyses?:     

  logo